Inclusion Criteria:

          -  PRIOR TO STEP 1 REGISTRATION:

          -  The patient must have a newly diagnosed unifocal intracranial meningioma, gross
             totally resected, and histologically confirmed as WHO grade II based upon pathology
             findings at the enrolling institution; WHO grade will be assigned according to WHO
             2016 criteria

          -  Gross total resection (GTR) will be interpreted as modified Simpson grade 1-3 without
             gross residual dural-based or extradural tumor; GTR must be confirmed both by modified
             Simpson grade and by post-operative magnetic resonance imaging (MRI) findings

          -  Step 1 registration must occur within 180 days of the initial surgery; within this 180
             day interval, a second surgery is permitted in order to achieve GTR, but even with a
             second surgery, step 1 registration must occur within 180 days of the initial
             resection

          -  For step 1 registration the operating neurosurgeon must provide the modified Simpson
             grade

          -  GTR must be confirmed on post-operative imaging following the most recent surgery;
             submission of both pre-operative and post-operative MRIs is required for patients; if
             a second surgery is performed, submission of post-operative MRI is required and
             pre-operative MRI is required only if obtained; all sequences obtained in the pre- and
             post-operative MR imaging are to be submitted to National Radiology Group (NRG)
             Oncology for study registration; imaging subsequent to enrollment must include pre and
             post gadolinium contrast-enhanced three-dimensional spoiled gradient (SPGR),
             magnetization-prepared rapid gradient echo (MP-RAGE), or turbo field echo (TFE) MRI
             scan and an axial T2 fluid attenuated inversion recovery (FLAIR) sequence; to yield
             acceptable image quality, the gadolinium contrast-enhanced three-dimensional SPGR,
             MP-RAGE, or TFE axial MRI scan should use the smallest possible axial slice thickness
             not exceeding 1.5 mm; the post-operative MRI must be completed within sufficient time
             to permit step 1 registration within 180 days of the initial resection; these same
             conditions apply in the setting of a second surgical procedure, although if a second
             surgery is completed, step 1 registration must still occur with 180 days of initial
             surgery; computed tomography (CT) imaging is not required, but may be obtained if
             desired clinically, for instance to assess calcifications or hyperostosis

          -  The patient or a legally authorized representative must provide study-specific
             informed consent prior to study entry

          -  If the patient is a primary English speaker, the patient must participate in the NCF
             and patient reported outcomes part of the study; if the patient is a primary French or
             Spanish speaker, the patient must participate in the patient reported outcomes part of
             the study

          -  NOTE: Central pathology review must occur between steps 1 and 2 of registration; once
             appropriate pathology specimens are received, central pathology review will occur
             within 15 days, and must confirm WHO grade II meningioma before the patient can
             proceed to step 2 registration and randomization

          -  PRIOR TO STEP 2 REGISTRATION:

          -  Histologically confirmed diagnosis of WHO grade II meningioma confirmed by central
             pathology review prior to step 2 registration

          -  History/physical examination, including neurologic examination within 60 days prior to
             step 2 registration

          -  Post-operative Zubrod performance status 0-1 within 60 days prior to step 2
             registration

          -  If the patient is a woman is of childbearing potential, a serum pregnancy test,
             obtained within 14 days prior to step 2 registration, must be negative, and, if
             randomized to receive radiation therapy, the woman must agree to use contraception

        Exclusion Criteria:

          -  Optic nerve sheath meningioma, spinal or other extracranial meningioma, multiple
             meningiomas, hemangiopericytoma

          -  Definitive evidence of metastatic meningioma

          -  Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free
             for a minimum of 3 years (carcinoma in situ of the breast, oral cavity, cervix,
             melanoma in situ, or other non-invasive malignancies are permissible)

          -  Previous radiotherapy to the scalp, cranium, brain, or skull base and
             radiation-induced meningiomas

          -  Major medical illnesses or psychiatric impairments, which in the investigators
             opinion, will prevent administration or completion of the protocol therapy and/or
             preclude informed consent; these include, but are not restricted to:

               -  Unstable angina and/or congestive heart failure requiring hospitalization at the
                  time of step 2 registration

               -  Transmural myocardial infarction within the last 6 months prior to step 2
                  registration

               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the time
                  of step 2 registration

               -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness
                  requiring hospitalization or precluding study therapy at the time of step 2
                  registration

               -  Type II neurofibromatosis (NF2)

               -  Ailments entailing substantial increases in sensitivity and side effect risk from
                  radiation therapy (ataxia telangiectasia, Nijmegen breakage syndrome, and human
                  immunodeficiency virus (HIV) with CD4 count < 200 cells/microliter); HIV testing
                  is not required for eligibility for this protocol, and known HIV positive
                  patients are eligible, provided they are under treatment with highly active
                  antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter
                  within 30 days prior to step 2 registration

               -  Inability to undergo MRI with and without contrast (e.g. claustrophobia, non-MRI
                  compatible implant or foreign body, etc) or receive gadolinium; note that
                  patients with severe claustrophobia are permitted on this study if they are
                  willing and able to undergo MRI with adequate sedation or anesthesia

          -  Pregnancy and/or nursing females